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Cytisine for smoking cessation in patients with tuberculosis: 
a multicentre, randomised, double-blind, placebo-controlled 
phase 3 trial
Omara Dogar, Ada Keding, Rhian Gabe, Anna-Marie Marshall, Rumana Huque, Deepa Barua, Razia Fatima, Amina Khan, Raana Zahid, 
Sonia Mansoor, Daniel Kotz, Melanie Boeckmann, Helen Elsey, Eva Kralikova, Steve Parrott, Jinshuo Li, Anne Readshaw, Aziz Sheikh, 
Kamran Siddiqi, on behalf of the TB and Tobacco Consortium*
Summary
Background Smoking cessation is important in patients with tuberculosis because it can reduce the high rates of 
treatment failure and mortality. We aimed to assess the effectiveness and safety of cystine as a smoking cessation aid 
in patients with tuberculosis in Bangladesh and Pakistan.
Methods We did a randomised, double-blind, placebo-controlled, trial at 32 health centres in Bangladesh and Pakistan. 
Eligible patients were adults (aged >18 years in Bangladesh; aged >15 years in Pakistan) with pulmonary tuberculosis 
diagnosed in the previous 4 weeks, who smoked tobacco on a daily basis and were willing to stop smoking. Patients 
were randomly assigned (1:1) to receive behavioural support plus either oral cytisine (9 mg on day 0, which was 
gradually reduced to 1·5 mg by day 25) or placebo for 25 days. Randomisation was done using pregenerated block 
randomisation lists, stratified by trial sites. Investigators, clinicians, and patients were masked to treatment allocation. 
The primary outcome was continuous abstinence at 6 months, defined as self-report (of not having used more than 
five cigarettes, bidis, a water pipe, or smokeless tobacco products since the quit date), confirmed biochemically by a 
breath carbon monoxide reading of less than 10 parts per million. Primary and safety analysis were done in the 
intention-to-treat population. This trial is registered with the International Standard Randomised Clinical Trial 
Registry, ISRCTN43811467, and enrolment is complete.
Findings Between June 6, 2017, and April 30, 2018, 2472 patients (1527 patients from Bangladesh; 945 patients from 
Pakistan) were enrolled and randomly assigned to receive cytisine (n=1239) or placebo (n=1233). At 6 months, 
401 (32·4%) participants in the cytisine group and 366 (29·7%) participants in the placebo group had achieved 
continuous abstinence (risk difference 2·68%, 95% CI –0·96 to 6·33; relative risk 1·09, 95% CI 0·97 to 1·23, 
p=0·114). 53 (4·3%) of 1239 participants in the cytisine group and 46 (3·7%) of 1233 participants in the placebo group 
reported serious adverse events (94 events in the cytisine group and 90 events in the placebo group), which included 
91 deaths (49 in the cytisine group and 42 in the placebo group). None of the adverse events were attributed to the 
study medication.
Interpretation Our findings do not support the addition of cytisine to brief behavioural support for the treatment of 
tobacco dependence in patients with tuberculosis.
Funding European Union Horizon 2020 and Health Data Research UK.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Tuberculosis is one of the most common chronic 
infectious diseases in the world: in 2018, an estimated 
10 million people had tuberculosis and around 
1·5 million deaths were attributed to the disease.1 
In 2017, about 85% of tuberculosis deaths occurred in 
Africa and southeast Asia where the prevalence of 
smoking is high.1 In the absence of smoking cessation 
services to treat nicotine dependence, the general 
population in these regions remain at risk of premature 
death and disabilities due to smoking. Assuming that 
the relative prevalence of smoking and tuberculosis 
remain stable, it is estimated that more than 40 million 
potentially avoidable tuberculosis-related deaths will be 
attributable to smoking by 2050.2 Many smokers in low-
income and middle-income countries (LMICs) have 
access to health services and each contact with these 
services provides an opportunity to incorporate 
smoking cessation treatment to help them quit. The 
integration of smoking cessation interventions within 
national and regional tuberculosis services in LMICs 
offers a viable solution to reduce the tuberculosis and 
tobacco-related disease burden.3
A tuberculosis treatment period of at least 6 months 
offers opportunities for health-care professionals to 
treat tobacco dependence alongside tuberculosis. Newly 
diagnosed patients with tuberculosis might be more 
motivated to stop smoking than smokers without 
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tuberculosis because of concerns about their illness 
and associated consequences.4 By reducing the risk of 
tuberculosis relapses and deaths and by preventing other 
tobacco-related chronic conditions, the potential health 
benefits of smoking cessation might be even higher 
among patients with tuberculosis than among smokers 
in the general population.5 Offering smoking cessation 
interventions to patients with tubercu losis should be 
routine and has been shown to be feasible in many 
contexts, although such interventions are rarely provided 
in LMICs.6,7 The scarcity of low-cost, effective, and safe 
smoking cessation treatment options in patients with 
tuberculosis, in addition to several other barriers, is 
widely acknowledged.8,9
Individual counselling, alone and in combination with 
pharmacotherapy, is an effective strategy for smoking 
cessation.10 In our previous trial of 1955 patients attending 
tuberculosis clinics in Pakistan, we found that two-fifths 
of smokers attained continuous abstinence at 6 months 
with behavioural support offered by health professionals.5 
However, the challenges of delivering 30–40 min of 
behavioural support within routine tuberculosis care 
including resource constraints,9 led to the development of 
a shorter optimised behavioural support intervention. 
In addition to the provision of behavioural support, 
substantial evidence indicates that nicotine replacement 
therapy and treatment with nicotine receptor partial 
agonists (bupropion, cytisine, and varenicline) are effec-
tive strategies to aid smoking cessation in the general 
population.11 The plant-based alkaloid cytisine is recom-
mended as an affordable intervention, especially for 
LMICs.12 The cost of cytisine is five to ten times lower 
than nicotine replacement therapy and varenicline, and 
has been found to be effective in moderate-to-heavy 
smokers.12 However, the effectiveness of cytisine in 
patients with tuberculosis in LMICs remains unknown. 
We aimed to investigate the effectiveness and safety of 
cytisine when given in combination with brief behavioural 
support in patients with tuberculosis in Bangladesh and 
Pakistan.
Methods
Study design and participants
We did a randomised, double-blind, placebo-controlled, 
trial at 32 health centres in Bangladesh and Pakistan. Sites 
were designated tuberculosis treatment centres run by the 
national tuberculosis control programmes of Bangladesh 
and Pakistan and were chosen on the basis of having the 
required resources and ability to recruit participants and 
take part in the research. The sites were 17 subdistrict 
hospitals in Bangladesh and 15 secondary care hospitals 
in Pakistan located in urban and rural areas.
Eligible patients were adults (aged >18 years in 
Bangladesh; aged >15 years in Pakistan, defined per the 
Research in context
Evidence before this study
We searched CINAHL, Embase, MEDLINE, the Cochrane 
Controlled Trials Register from inception to June 1, 2020, 
for randomised controlled trials of smoking cessation 
interventions in low-income and middle-income countries 
(LMICs) in adult smokers with tuberculosis published in 
English. Two quasi-experimental studies indicated that 
offering behavioural support to patients with tuberculosis 
might result in high rates of smoking cessation and improve 
clinical outcomes. Our previous smoking cessation trial of 
behavioural support with and without bupropion in a large 
sample of patients with suspected and confirmed tuberculosis 
in Pakistan found that patients given behavioural support 
were seven to eight times more likely to have stopped 
smoking than those given usual care at 6 months. A higher 
cessation rate was observed in patients with confirmed 
tuberculosis than those with suspected tuberculosis. However, 
the addition of bupropion to the behavioural support 
intervention had no significant effect on the number of 
patients who had stopped smoking at 6 months. Our search 
yielded no other trials of pharmacological treatment 
(eg, nicotine replacement therapy, varenicline, or cytisine) for 
smoking cessation in patients with tuberculosis. Although 
evidence indicates that behavioural support is effective for 
smoking cessation in patients with tuberculosis, to the best of 
our knowledge, no randomised trials have been done 
investigating the effect of cytisine for smoking cessation in 
such patients.
Added value of this study
We recruited a large sample of patients with tuberculosis in 
Bangladesh and Pakistan to assess the effectiveness of cytisine 
with behavioural support for smoking cessation compared with 
behavioural support alone. To the best of our knowledge, this is 
the largest trial of cytisine for smoking cessation to date, and it 
is the first such trial to be done across two countries. Although 
the proportion of patients who achieved abstinence at 
6 months was high in both groups, cytisine had no clinically or 
statistically significant advantage for smoking cessation when 
added to behavioural support in patients with tuberculosis.
Implications of all the available evidence
When offered behavioural support, a large proportion of 
patients with tuberculosis quit smoking, often more readily 
than general smokers. Patients who stop smoking are also 
more likely to recover from tuberculosis than those who do not. 
Compelling evidence supports advising and counselling 
patients with tuberculosis to quit smoking. However, current 
evidence does not support supplementation of behavioural 
support with pharmacological treatment in patients with 
tuberculosis. More research on strategies for the 
implementation of behavioural support for smoking cessation 
in routine tuberculosis care in LMICs is needed.
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national tuberculosis control programmes of respective 
countries) with pulmonary tuberculosis diagnosed in the 
previous 4 weeks, who smoked tobacco on a daily basis and 
were willing to stop smoking. Patients with extrapulmonary 
tuberculosis, tuberculosis complications (retreatment or 
any drug resistance), those receiving streptomycin or para-
aminosalicylic acid, and patients using tobacco dependence 
medication were excluded. Patients who were pregnant or 
lactating, had a history of myocardial infarction, stroke, 
or severe angina within the previous 2 weeks, had 
uncontrolled high blood pressure, severe renal impairment 
requiring dialysis or known diagnosis of schizophrenia or 
epilepsy were also excluded.13
The study protocol (appendix 3 p 36)13 was approved by 
the Ethics Committee of the University of York (York, 
UK) and the national ethics committees in Bangladesh 
and Pakistan. The trial was done in accordance with the 
Declaration of Helsinki and the national regulatory 
requirements. The trial was overseen by an Independent 
Steering Committee and Data Monitoring Committee 
(appendix 3 pp 2, 3). All participants provided written 
informed consent.
Randomisation and masking
Patients were randomly assigned (1:1) to receive cytisine 
plus behavioural support or placebo plus behavioural 
support for 25 days using permuted blocks of eight, 
stratified by trial sites. Randomisation lists were 
pregenerated by the trial statistician at York Trials Unit 
(University of York) and held securely at the offices of the 
study partners (ARK Foundation [Dhaka, Bangladesh] 
and The Initiative [Islamabad, Pakistan]) for sequential 
allocation by masked trial coordinating staff. Inves-
tigators, clinicians, and patients were masked to treatment 
allocation. To maintain masking, medication packs were 
identical and cytisine and placebo capsules were identical 
in appearance, smell, and taste. Code-break envelopes 
were prepared separately for each medication pack, which 
contained the true allocation, for emergency unmasking 
as per the protocol.13
Procedures
A brief behavioural support intervention for smoking 
cessation was offered to all patients (appendix 3 p 5). The 
intervention was delivered by tuberculosis health workers 
in two face-to-face sessions: a 10-min session on the day 
of enrolment (day 0) and a 5-min session on the quit date 
(±2 days). The starting study drug dose was 9 mg cytisine 
(Desmoxan; Aflofarm, Pabianice, Poland) or placebo 
administered orally as six 1·5 mg capsules per day, 
which was gradually reduced to 1·5 mg (one capsule) by 
day 25, with a quit date set for day 5. The complete 
dosing schedule is shown in appendix 3 (p 10). The trial 
medication was dispensed for free by site researchers in 
two batches: patients were provided medication for 7 days 
on day 0 (at enrolment), followed by medication for 
18 days on day 5, to complete the course. Clearly labelled 
colour-coded boxes were used for each block of varying 
dosing regimen (days 1–3, 4–7, 8–12, 13–16, 17–20, 21–24, 
and 25) and blister packs were cut out to contain the 
exact daily dosage. To further simplify the dosing regi-
men, scheduling cards were completed in the patient’s 
presence to assist them in remembering when to take 
the trial medication.
Patients were followed up on day 5, weeks 5, 9, and 12, 
and at 6 and 12 months. These timepoints were designed 
to correspond to routine tuberculosis clinic visits, with 
the exception of visits on day 5 (to monitor for adverse 
drug reactions) and 12 months (to assess secondary 
outcomes), which were supplementary to the routine 
visits. Participants were not paid any incentives to attend 
follow-up visits, but they were reimbursed for travel 
expenses to attend visits that were not part of routine 
tuberculosis care.
Outcomes
The primary endpoint was continuous abstinence at 
6 months.14 Continuous abstinence was defined as self-
report (of not having used more than five cigarettes, 
bidis, a water pipe, or smokeless tobacco products since 
the quit date), verified biochemically by a breath carbon 
monoxide reading of less than 10 parts per million (ppm). 
A negative urine cotinine test (NicAlert test strip [Nymox 
Pharmaceutical, Quebec, QC, Canada]; One Step urine 
test strip [Home Health UK, Bushey, UK]) was also 
required for participants who reported smokeless tobacco 
use at baseline.
Secondary outcomes were continuous abstinence at 
12 months; point abstinence at weeks 5 and 12, and 6 and 
12 months; early lapses (defined by a self-report of tobacco 
use [even once] after the quit date, but having point 
abstinence at week 5) and late lapses (defined by a self-
report of tobacco use [even once] between week 5 and 
week 12, but showing point abstinence at week 5 and 
week 12); clinical tuberculosis score;15 chest X-ray grade; 
sputum smear microscopy; adherence to tuberculosis 
treatment; tuberculosis treatment outcome (success, 
failure, default, relapse, or death; appendix 3 pp 58–59); 
Mood and Physical Symptoms Scale score; Strength of 
Urges To Smoke scores; and time to first use of tobacco 
product of the day (from the Heaviness of Smoking 
Index16).17 Full details for all secondary outcomes are 
included in appendix 3 (pp 58–59). Medication adherence 
was measured using a pill count and a 7-day recall 
approach.18 Information about supplemental smoking 
cessation advice sought by the patients, during the 
6 months since quit date, was also reported to provide 
context for interpretation of study findings.
We did sensitivity analyses of the primary outcome by 
adjusting for baseline nicotine dependency, age, sex, and 
type of tobacco use, and did a complete case analysis, 
excluding patients who had died, were lost to follow-up, 
had missing self-reported abstinence data or either 
missing or invalid biochemical test data. We also did 
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exploratory subgroup analyses of the primary outcome 
by age, sex, type of tobacco use, tuberculosis severity, 
country of residence, and socioeconomic status.
Safety was assessed through adverse event collection 
up to week 9 and adverse events were collected through 
self-reports completed by patients using checklists based 
on common adverse events reported in the product insert 
of Desmoxan and previous studies of cytisine.13 Patients 
who reported any moderate-to-severe symptoms were 
reviewed by the site-designated independent clinician, to 
determine the severity and expectedness, and to ascertain 
whether the event was associated with study treatment. 
The country coordinating office was notified of all serious 
adverse events within 24 h of site researchers becoming 
aware of an event, who in turn notified the York trial 
team within 24 h. Medically qualified staff at the country 
coordinating centres confirmed the causality and 
expectedness of events, and classified adverse events 
according to the Medical Dictionary for Regulatory 
Activities (MedDRA).13
Data were initially collected on paper case report forms 
and then checked and entered at the country level 
through a web interface into a central trial database with 
inbuilt validation rules, hosted by York Trials Unit. 
Data were extracted periodically by the trial statisticians 
for the purpose of trial coordination and reporting to 
the independent oversight committees. Queries were 
resolved with country trial teams on an ongoing basis.
Statistical analysis
On the basis of cessation rates reported in previous 
trials,7,19 assuming an attrition rate of 10%,7 we calculated 
that a sample size of 1074 patients in the cytisine group 
and 1074 patients in the placebo group would provide 
80% power to detect a 6% difference in the proportion of 
patients who had achieved continuous abstinence rates 
at 6 months between cytisine and placebo groups. Thus, 
we aimed to recruit 1194 patients in each group.
The number and proportion of abstinent participants 
were reported by treatment group. The between-group 
difference was presented as the risk difference and 
relative risk (RR) with 95% CIs. A p value for the effect of 
allocation was derived using logistic regression, with trial 
sites included as random-effects using robust SEs. 
Missing primary outcome data were treated as a negative 
outcome (ie, not abstinent). Any primary outcome data 
collected more than 4 weeks before or after the 6-month 
follow-up were also treated as a negative outcome. 
Secondary outcomes were analysed in the same manner. 
Since a carbon monoxide cutoff of less than 10 ppm 
was used for biochemical verification of self-reports of 
abstinence, participants reporting continuous abstinence 
at 6 months post-randomisation with a carbon monoxide 
reading of 10 ppm or more, could not be verified. We 
regarded these participants as not abstinent; their high 
carbon monoxide reading indicated that they were most 
likely still smoking despite reporting abstinence.
Continuous tuberculosis outcomes and nicotine 
dependency were analysed using linear mixed-effect 
regression models for all available timepoints. The 
number of adverse events (serious and non-serious), 
patients with any adverse event, and adverse events per 
patient in the two groups was compared using a χ² test. 
Adherence to study medication was categorised as 
good (≥80%), moderate (≥50%) and poor (<50%),13 on the 
basis of the number of days participants self-reported to 
have taken medications as prescribed.
The costs of treatment for behavioural support and trial 
medications were collected in local currencies and 
converted to purchasing power parity (PPP) to pool the 
results across the two countries. Placebo medications 
were considered at zero cost. Costs were presented as 
purchasing power parity US$ (PPP US$) 2017 values. 
Missing values were imputed using multiple imputation. 
The imputation model included other health-care costs 
and quality of life for economic evaluation, which will be 
reported elsewhere.
All prespecified primary, secondary and safety analyses 
were done by intention to treat whereby patients were 
analysed according to their allocated treatment group 
regardless of their compliance with the study drug 
schedule. Two-sided p values of less than 0·05 were 
considered to indicate statistical significance. All statis-
tical analysis were done using Stata (version 16.0).
This trial is registered with the International Standard 
Randomised Clinical Trial Registry, ISRCTN43811467.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between June 6, 2017, and April 30, 2018, of 13 934 (18%) 
patients with tuberculosis assessed, 2472 patients 
(1527 patients from Bangladesh; 945 patients from 
Pakistan) were enrolled and randomly assigned to receive 
behavioural support plus either cytisine (n=1239) or 
placebo (n=1233; figure; appendix 3 p 12). 11 462 (82%) 
patients with tuberculosis were excluded, predominantly 
because they were not daily smokers. Of the 2472 patients 
enrolled, 1142 (92%) of 1239 patients in the cytisine group 
and 1130 (92%) of 1233 patients in the placebo group 
completed the 6-month follow-up assessment (figure).
Baseline characteristics were balanced between the 
two treatment groups (table 1). Most participants were 
men (2448 [99%] of 2472 patients) and had smoked a 
mean of 11·1 cigarettes per day (SD 8·6) for the previous 
23 years, with a quarter reporting they had previously 
attempted to quit.
At 6 months, 675 (54·5%) of 1239 participants in the 
cytisine group and 644 (52·2%) of 1233 participants in the 
For more on Desmoxan see 
www.desmoxan.pl
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placebo group reported continuous abstinence, which was 
biochemically-verified in 401 (32·4%) of 1239 participants 
in the cytisine group and 366 (29·7%) of 1233 participants 
in the placebo group (table 2). We found no difference 
in the proportion of patients achieving biochemically-
verified continuous abstinence between the groups (risk 
difference 2·68%, 95% CI –0·96 to 6·33; RR 1·09, 95% CI 
0·97 to 1·23). Overall, of the 1322 patients who self-
reported continuous abstinence at 6 months, 767 (58%) 
were biochemically verified.
The analysis remained robust to additional adjustments 
for baseline level of nicotine dependence, age, sex, and 
Figure: Trial profile
ITT=intention-to-treat. *Exclusions before randomisation could be for more than one reason. †Numbers of patients with missing data were not mutually exclusive 
across the 6 month and 12 month analyses; 47 patients receiving cytisine had missing data at both months 6 and 12 and 43 patients receiving placebo had missing data 
at months 6 and 12. ‡A status of continued smoking was inferred for any missing data. 
1239 assigned cytisine 1233 assigned placebo
11 462 excluded*
10 779 did not smoke tobacco on a daily basis
3390 not newly diagnosed with pulmonary tuberculosis
2797 unable to provide consent
826 had tuberculosis complications, multidrug-resistant 
         tuberculosis, miliary or extrapulmonary tuberculosis
721 aged <15 years (Pakistan) or <18 years (Bangladesh)
521 using streptomycin
270 Had uncontrolled high blood pressure
211 were pregnant, lactating, or planning to become pregnant
69 had a history of myocardial infarction, stroke, or attack of 
       severe angina in the previous 2 weeks
59 had severe renal impairment
53 declined to participate
7 had schizophrenia or epilepsy
3 using tobacco dependence medication
1128 self-reported abstinence data available at week 5
1157 self-reported abstinence data available at week 12
1140 self-reported abstinence data available at week 5 
1153 self-reported abstinence data available at week 12
1239 included in the ITT analysis at 6 months (primary outcome)
1142 self-reported abstinence data available, of which 1121 biochemically 
verified (continuous smoking inferred for non-verified data)
97 continuous smoking inferred for missing data‡
1233 included in the ITT analysis at 6 months (primary outcome)
1130 self-reported abstinence data available, of which 1111 biochemically 
verified (continuous smoking inferred for non-verified data)
103 continuous smoking inferred for missing data‡
1239 included in the ITT analysis at 12 months 
1106 self-reported abstinence data available, of which 1064 biochemically 
verified (continuous smoking inferred for non-verified data)
133 continuous smoking inferred for missing data
1233 included in the ITT analysis at 12 months 
1121 self-reported abstinence data, available of which 1072  biochemically 
verified (continuous smoking inferred for non-verified data)
112 continuous smoking inferred for missing data
2472 randomised
39 excluded before primary outcome at 6 months
36 died
1 left country to work abroad
1 change of diagnosis to extra-pulmonary tuberculosis
1 parents did not allow further follow-up
58 with missing data at 6 months†
38 excluded before primary outcome at 6 months
34 died
1 left country to work abroad
1 change of diagnosis to extra-pulmonary tuberculosis
1 withdrew consent 
1 had tuberculosis complications
65 with missing data at 6 months†
13 934 assessed for eligibility
12 excluded before outcome at 12 months
12 died
82 with missing data at 12 months†
8 excluded before outcome at 12 months
8 died
66 with missing data at 12 months†
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type of tobacco use; excluding the 70 patients who died 
before 6 months follow-up and for whom a trial outcome 
of continued smoking status was imputed; and a 
complete case analysis further excluding 170 patients 
with missing data (comprising seven patients excluded 
for other reasons, 123 patients lost to follow-up and 
40 patients who indicated self-reported quitting but 
for whom no biochemical verification was available; 
appendix 3 p 17). Reasons for missing data were primarily 
associated with loss to follow-up or missing biochemical 
verification data.
The proportion of patients who had achieved self-
reported abstinence was higher in the cytisine group than 
the placebo group at 5 weeks (risk difference 4·40, 95% CI 
0·54 to 8·27), 12 weeks (3·14, –0·79 to 7·07), 6 months 
(4·42, 0·58 to 8·26), and 12 months (3·32, –0·38 to 7·02; 
table 2), but these differences were not statistically 
significant. However, we found no difference between the 
groups in the proportion of patients with biochemically-
verified continuous absti nence at 12 months (2·64, 
–0·71 to 5·98). Of the participants who were abstinent 
at 5 weeks, a similar proportion had early lapses in the 
two groups (0·78, –1·21 to 2·77; appendix 3 p 18). The 
proportion of patients who had late lapses between weeks 5 
and 12 were also similar between the groups (0·05, 
–1·63 to 1·72). Of the 839 patients who reported smoked 
tobacco use only at baseline and self-reported some form 
of tobacco use at 6 months, 717 (85%) remained tobacco 
smokers only (n=347 in the cytisine group; n=370 in the 
placebo group), 61 (7%) reported smoked and smokeless 
tobacco use (n=31 in the cytisine group; n=30 in the 
placebo group) and 61 (7%) reported use of smokeless 
tobacco only at 6 months (n=31 in the cytisine group; n=30 
in the placebo group).
At 6 months, 1007 (89·5%) of 1125 patients in the 
cytisine group and 1018 (91·2%) of 1116 patients in the 
placebo group had achieved tuberculosis treatment 
success (ie, cured or had completed treatment) and at 
12 months, 899 (81·4%) of 1105 had achieved treatment 
success in the cytisine group compared with 927 (83·0%) 
of 1117 patients in the placebo group (table 3). Mean 
clinical tuberculosis scores decreased from 3·4 (SD 1·6) 
at baseline to 1·0 (1·3) at 12 months in both treatment 
groups (appendix 3 pp 13, 19–20). We observed no 
significant differences in the outcomes of sputum smear 
microscopy, tuberculosis treatment adherence, and chest 
x ray grade between the groups (appendix 3 pp 21–23). 
Mood and Physical Symptoms Scale and Strength for 
Urges To Smoke scale scores were similar between the 
groups (appendix 3 pp 14, 24). Self-reported medi cation 
compliance was high (>90%) and similar in both treat-
ment groups (appendix 3 p 25). Reasons for withdrawals 
from treatment and non-compliance are listed in 
appendix 3 (pp 26, 27).
An insufficient number of women (n=24) were enrolled 
to enable meaningful subgroup analysis by sex. Among 
individuals who were exclusive smokers (ie, not dual 
tobacco users), a small absolute difference was identified 
in the proportion of patients who had achieved continuous 
abstinence at 6 months between the cytisine and placebo 
groups, but this difference was not statistically significant 
(399 [34%] of 1157 patients in the cytisine group vs 





Age, years 42·5 (14·3) 42·4 (14·2)
Sex
Female 12 (1·0%) 12 (1·0%)
Male 1227 (99·0%) 1221 (99·0%)
Body-mass index* 18·5 (3·1) 18·6 (3·3)
Marital status
Single 155 (12·5%) 163 (13·2%)
Separated 2 (0·2%) 6 (0·5%)
Married 1067 (86·1%) 1044 (84·7%)
Divorced 1 (0·1%) 3 (0·2%)
Widowed 14 (1·1%) 17 (1·4%)
Tuberculosis severity score†
Class 1 130 (10·5%) 134 (10·9%)
Class 2 587 (47·4%) 570 (46·2%)
Class 3 508 (41·0%) 514 (41·7%)
Class 4 14 (1·1%) 15 (1·2%)
Tobacco use‡
Cigarettes 1152 (93·0%) 1149 (93·2%)
Bidi 129 (10·4%) 130 (10·5%)
Hookah 46 (3·7%) 48 (3·9%)
Electronic cigarettes 1 (0·1%) 2 (0·2%)
Smokeless tobacco 82 (6·6%) 88 (7·1%)
Other 35 (2·8%) 28 (2·3%)
Cigarettes smoked per day§ 11·1 (8·1) 11·0 (9·0)
Duration of smoking, years 23·4 (14·2) 23·3 (13·8)
Previously attempted to quit 324 (26·2%) 330 (26·8%)
Strength of urges to smoke 
score¶||
2·8 (1·1) 2·8 (1·1)
Time to first daily smoke, min**††
<5 min 348 (28·1%) 332 (26·9%)
5–30 426 (34·4%) 418 (33·9%)
31–60 217 (17·5%) 220 (17·8%)
>60 246 (19·9%) 262 (21·2%)
Data are mean (SD) or n (%). Some percentages might not sum to 100 because of 
rounding. *Data missing for two patients in the cytisine group and one patent in 
the placebo group. †Based on the presence of eight tuberculosis related signs and 
symptoms (eg, chest pain or being underweight), summarised into four severity 
classes: class 1 (0–1 symptoms), class 2 (2–3 symptoms), class 3 (4–7 symptoms), 
and class 4 (8 symptoms).15 ‡Categories were not mutually exclusive—ie, some 
patients reported more than one type of tobacco use. §Data missing for 
91 patients in the cytisine group and 84 patients in the placebo group. ¶Data 
missing for one patient in the cytisine group. ||Urge to smoke in the past 24 h was 
scored on a scale from 0 to 5, whereby 0 indicated no urge to smoke and 
5 indicated a continuous urge to smoke. **Tobacco dependence was measured 
using the time to first use of tobacco product after waking component of the 
Heaviness to Smoke Index.17 ††Data missing for two patients in the cytisine group 
and one patient in the placebo group.
Table 1: Baseline characteristics
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95% CI 0·99 to 1·25; appendix 3 p 15). In the placebo 
group, the proportion of patients who had achieved 
continuous abstinence at 6 months was higher among 
dual users (ie, those who smoked and reported smokeless 
tobacco at baseline) than those who only smoked tobacco 
(p=0·024 for the interaction with allo cated treatment; 
appendix 3 p 15). However, differences in abstinence rates 
between dual users and exclusive smokers were not 
consistent at earlier timepoints, and the number of 
participants was small (12 [7%] of 170 dual users were 
abstinent at 6 months). The difference in the proportion of 
participants who had achieved continuous abstinence at 
6 months between the cytisine and placebo groups was 
slightly larger in Pakistan than Bangladesh, but this 
difference was not statistically significant (6% in Pakistan 
[157 (33%) of 476 patients in the cytisine group and 
127 (27%) of 469 patients in the placebo group] vs 
1% in Bangladesh [244 (32%) of 763 patients in the cytisine 
group and 239 (31%) of 764 patients in the placebo group]); 
p=0·118 for the interaction term; appendix 3 p 15).
The mean cost of cytisine was PPP US$48·27 (SE 0·36) 
per participant in the cytisine group. The mean costs 
of training health-care workers and delivering behav-
ioural support were similar between the two groups 
(PPP US$60·65 [SE 0·41] in the cytisine group vs 
PPP US$12·37 (SE 0·08) in the placebo group; between-
group difference PPP US$48·28 [95% CI 47·71–48·80]).
53 (4·3%) of 1239 participants in the cytisine group 
and 46 (3·7%) of 1233 participants in the placebo group 
reported serious adverse events (94 events in the cytisine 
group and 90 events in the placebo group), but this 
difference was not statistically significant (RR 1·07, 
95% CI 0·89 to 1·29; p=0·488; table 4). Serious adverse 
events included 91 deaths (49 in the cytisine group and 
42 in the placebo group). Other serious adverse events 
reported more than twice were breathing difficulties (n=4 
events in the cytisine group; n=6 events in the placebo 
group), fever (n=1 cytisine group; n=3 placebo group), 
lung cancer (n=9 cytisine group; n=6 placebo group), 
myocardial infarction (n=8 cytisine group; n=5 placebo 
group), stroke (n=3 cytisine group; n=2 placebo group), 
chest pain (n=1 cytisine group; n=2 placebo group), and 
haemoptysis (n=2 cytisine group, n=1 placebo group). 
None of these serious adverse events (including 
deaths) were attributed to the study medication. Expected 
and other reported non-serious adverse events are 
summarised in appendix 3 (pp 29, 30). 98 (7·9%) of 
1239 patients in the cytisine group and 86 (7·0%) of 
1233 patients in the placebo group had one or more non-
serious adverse events (RR 1·13, 95% CI 0·86 to 1·50). A 
full list of serious and non-serious adverse events are 
shown in appendix 3 (pp 33–35).
594 (24%) of 2472 enrolled patients sought supple -
mental smoking cessation advice (appendix 3 p 35), the 
majority of the supplemental smoking cessation advice 
was provided by public hospitals; the mean number of 
times a patient sought advice was similar between the 
cytisine group (2·5 times [SD 1·6]) and the placebo 
group (2·5 times [2·0]). The proportion of patients who 
sought supplemental smoking cessation advice was 
similar between the cytisine (n=299 [26%]) and placebo 
(n=295 [26%]) groups.
Discussion
The proportion of patients who achieved abstinence at 
6 months did not significantly differ between the 







Risk ratio  
(95% CI)
Continuous abstinence at 6 months
Self-reported 675 (54·5%) 644 (52·2%) 2·25% (–1·68 to 6·18) 1·04 (0·97 to 1·12)
Biochemically 
verified*
401 (32·4%) 366 (29·7%) 2·68% (–0·96 to 6·33) 1·09 (0·97 to 1·23)
Continuous abstinence at 12 months
Self-reported 600 (48·4%) 585 (47·4%) 0·98% (–2·96 to 4·92) 1·02 (0·94 to 1·11)
Biochemically verified 309 (24·9%) 275 (22·3%) 2·64% (–0·71 to 5·98) 1·12 (0·97 to 1·29)
Self-reported point abstinence
5 weeks 762 (61·5%) 704 (57·1%) 4·40% (0·54 to 8·27) 1·08 (1·01 to 1·15)
12 weeks 685 (55·3%) 643 (52·1%) 3·14% (–0·79 to 7·07) 1·06 (0·99 to 1·14)
6 months 509 (41·1%) 452 (36·7%) 4·42% (0·58 to 8·26) 1·12 (1·01 to 1·24)
12 months 426 (34·4%) 383 (31·1%) 3·32% (–0·38 to 7·02) 1·11 (0·99 to 1·24)
Data are n (%). *Primary outcome (continuous abstinence at 6 months, defined as self-report [of not having used more 
than five cigarettes, bidis, waterpipe sessions, or smokeless tobacco products since the quit date], confirmed 
biochemically by a breath carbon monoxide reading of less than 10 parts per million).
Table 2: Primary and key secondary tobacco cessation outcomes









Cured or completed 
treatment at 6 months
1007/1125 
(89·5%)
1007 (81·3%) 1018/1116 (91·2%) 1018 (82·6%)
Cured or completed 
treatment at 12 months
899/1105 
(81·4%)
899 (72·6%) 927/1117 (83·0%) 927 (75·2%)
Data are n/N (%) or n (%).





Total number of severe adverse events 94 90
Possibly/probably related to study drug 0 0
Patients with one or more severe 
adverse events
53 (4·3%) 46 (3·7%)
Severe adverse events in ten or more individuals
Deaths 49 (4·0%) 42 (3·4%)
Lung cancer 9 (0·7%) 6 (0·5%)
Myocardial infarction 8 (0·6%) 5 (0·4%)
Difficulty breathing 4 (0·3%) 6 (0·5%)
Data are n or n (%).
Table 4: Serious adverse events
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had no additional benefit for smoking cessation in 
patients with tuberculosis. The risk difference in 
6-month continuous abstinence rates between the 
two treatment groups (2·68%) was less than the 
difference of 6% that would represent a clinically 
significant difference. Moreover, the observed risk 
difference was not statistically significant, although the 
upper limit of the 95% CI was above 6%. This finding 
was consistent across all secondary tobacco cessation 
outcomes. The number of adverse events were balanced 
between the two groups. No serious adverse events were 
attributed to study medication, and cytisine seemed 
to be well-tolerated. The proportion of patients with 
available data for continuous abstinence (92%) was high 
and similar in both groups.
A 2018 meta-analysis of all cytisine trials (n=4216; 
sample size range 150–1214) showed that smoking 
cessation rates among patients given cytisine improved 
by 75% compared with patients given placebo.12 Add-
itionally, a non-inferiority trial found cytisine to be more 
effective than nicotine replacement therapy.20 However, 
the absolute difference in cessation rates between 
cytisine and placebo in our trial was lower than that 
reported in previous trials, possibly due to certain 
contextual and population differences. In subgroup 
analyses, a non-significant difference in cessation rates 
in favour of cytisine was noted in those who smoked 
exclusively (34% in the cytisine group vs 31% in the 
placebo group). By contrast to our trial, previous trials 
recruited healthy participants. The participants included 
in our study were recently diagnosed with pulmonary 
tuberculosis and, as part of behavioural support, learned 
about the association between smoking and their 
condition. The proportion of patients in the placebo 
group who met the primary endpoint (29·7%) indicates 
that the participants had a strong motivation to quit. 
In our previous trial of patients presenting with 
tuberculosis symptoms, 41% of participants achieved 
abstinence by 6 months with behavioural support; 
however, the sessions were longer in duration 
(30–45 min) than those in the current study.7 This 
difference in intrinsic motivation between specific 
groups and the general population is also exemplified 
during pregnancy when high quit rates are achieved 
with behavioural support alone.21 Another key difference 
between our participants and those included in the 
previous cytisine trials is the extent of nicotine addiction. 
The mean number of cigarettes smoked per day in 
previous cytisine trials were higher (19·3 cigarettes per 
day [SD 11·9];20 23·0 cigarettes per day [8·7]22) than in 
our trial (11·1 cigarettes per day [8·1]). Generally, heavy 
smokers with high nicotine dependence are more 
likely to benefit from medication23 by attenuating 
their withdrawal symptoms than are light smokers.12 
However, the proportion of participants in Pakistan 
(who smoked a mean 12·9 cigarettes per day) who had 
achieved abstinence by 6 months (33% in the cystine 
group vs 27% in the placebo group) did not signifi-
cantly differ from the proportion in Bangladesh 
(mean 9·8 cigarettes per day; 32% achieved abstinence 
in the cystine group vs 31% achieved abstinence in the 
placebo group). Moreover, our pragmatic trial was done 
in clinical settings where some loss of effectiveness is 
expected when compared with explanatory trials.
To the best of our knowledge, this is the largest trial of 
cytisine for smoking cessation to date, and is the first 
such trial to be done across two countries. Bangladesh 
and Pakistan were selected because of existing partner-
ships with academics and tuberculosis programmes, 
local knowledge, and previous experience of doing trials 
in these countries. With the exception of a small trial 
(n=171) in Kyrgyzstan,24 this is the first trial of cytisine 
and one of the few smoking cessation trials to be done in 
LMIC settings. Other strengths of this study were the 
rigor and quality with which the trial was done and 
the assessment of abstinence at 12 months, which 
represents a longer follow-up than is usually done in 
smoking cessation trials, and tubercu losis outcomes. 
Approximately, 42% of participants who self-reported 
continuous abstinence at 6 months could not be verified 
biochemically. This finding is consistent with the 
accuracy of self-report from other smoking cessation 
clinical trials25 and our previous trial7 in patients 
suspected to have tuberculosis in Pakistan, where about 
half (49%) of the self-reports could be biochemically 
validated. This difference could be explained by multiple 
factors including social desirability in response to 
participation in a smoking cessation trial or wanting to 
avoid stigma that might be associated with continued 
smoking considering that it will worsen tuberculosis 
outcomes,25 and poor air quality that is likely to be a 
contributor to higher carbon monoxide levels than the 
cutoff used.26
Our trial had some limitations. First, our assessment 
of adherence to the trial medication was self-reported.27 
Considering the complexity of the cytisine dosing 
schedule and anti-tuberculosis comedication, adherence 
to study medication might have been lower than 
reported. Although a lower level of adherence would 
not influence the difference between the cytisine and 
placebo groups, it might have resulted in a lower 
proportion of patients achieving abstinence across the 
two groups. Second, the stability and pharmacovigilance 
of cytisine have not yet been assessed in non-European 
climates. Although we ensured medication storage 
conditions were within the manufacturer’s recom men-
dations, exposures to high temperatures or humidity 
might have led to instability and loss of efficacy. 
Third, our trial was not powered to detect differences 
in secondary tuberculosis outcomes or for subgroup 
analysis. Fourth, only a small number of women were 
recruited, which might limit the generalisability of our 
findings; however, this is likely to be due to low smoking 
prevalence among women in south Asia and might also 
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be due to sex-specific barriers in seeking cessation 
support (eg, stigma), which requires further exploration.28 
The effectiveness of cytisine requires assessment when 
administered using simplified dosing schedules, in 
combination with other medications, with intensive 
behavioural support or without behavioural support. 
Pharmacovigilance studies are also needed to assess the 
stability of cytisine in a variety of geographical regions. 
Affordable smoking cessation aids such as cytisine are 
currently under consideration for licensing in high-
income countries, thus a need exists to assess such 
options for smoking cessation in LMICs and in smoking-
attributable disease groups.
The addition of cytisine to brief behavioural support 
was not effective for smoking cessation in routine 
tuberculosis care. Health professionals should continue 
to question patients with tuberculosis about their 
smoking status and offer interventions to support 
smoking cessation, consistent with current national or 
international guidance.
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